肝门胆管癌不同临床分期及分型对手术根治性切除及预后的评估价值

辛奇; 于小源; 刘兴凯; 张平

doi:10.3969/j.issn.1001-5256.2020.02.053

肝门胆管癌不同临床分期及分型对手术根治性切除及预后的评估价值

DOI: 10.3969/j.issn.1001-5256.2020.02.053

1. 西安市第三医院普外科二病区
2. 西安市第三医院血液与肿瘤科
3. 吉林大学第一医院肝胆外一科

基金项目:

国家自然科学基金青年科学基金项目(8180081118)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1125
- HTML全文浏览量: 56
- PDF下载量: 232
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-11
- 出版日期: 2020-02-20

Value of clinical staging and typing of hilar cholangiocarcinoma in evaluating radical resection and prognosis

Second Ward of Department of General Surgery,Xi'an Third Hospital

Research funding:

摘要

摘要:
肝门胆管癌（HCCA）是一种胆管黏膜上皮癌,累及肝总管、左右肝管及其汇合部。其起病隐匿,当出现黄疸时大多已进入晚期,被公认为外科领域的治疗难题。根治性切除是治疗HCCA的最佳方法,是影响肿瘤复发率和患者生存期的重要因素。因此,术前评估肿瘤的可切除性是治疗HCCA的重要一步。目前,HCCA的分型和分期方法主要有8种:Bismuth-Corlette分型、改良T分期、TNM分期、JSBS分期、Gazzaniga分期、国际胆管癌协会分期系统、梅奥分期、Blechacz分期。在临床实践中,不同分期和分型均存有各自的优缺点。主要对HCCA的分期和分型方法作一系统综述,重点评述各分期和分型在术前评估根治性切除和预后方面的临床价值。
- Klatskin肿瘤 /
- 肿瘤分期 /
- 外科手术 /
- 预后
Abstract:
Hilar cholangiocarcinoma( HCCA) is a malignant tumor arising from the epithelium of the bile duct,which involves the common hepatic duct,the left and right hepatic ducts,and the confluence areas of these bile ducts. HCCA has an insidious onset and most patients are in the advanced stage when jaundice is observed,and therefore it is considered a difficult issue in the field of surgery. Radical resection is the optimal method for the treatment of HCCA and has great influence on recurrence rate of tumor and patients' survival time. Therefore,preoperative evaluation of tumor resectability is an important step of HCCA treatment. At present,there are eight main methods for HCCA staging and typing,i. e.,Bismuth-Corlette classification system,modified T staging system,TNM staging system,JSBS staging system,Gazzaniga staging system,International Cholangiocarcinoma Group staging system,Mayo staging system,and Blechacz staging system. Each staging and typing system has its own advantages and disadvantages in clinical practice. This article reviews the staging and typing methods for HCCA,with a focus on the clinical value of each staging and typing system in preoperative evaluation of radical resection and prognosis.
- Klatskin tumor /
- neoplasm staging /
- surgical procedures,operative /
- prognosis

HTML全文

参考文献(31)

[1] MELENHORST MC,SCHEFFER HJ,VROOMEN LG,et al.Percutaneous irreversible electroporation of unresectable hilar cholangiocarcinoma(klatskin tumor):A case report[J]. Cardiovasc Intervent Radiol,2016,39(1):117-121.

[2] MADHUSUDHAN KS,GAMANAGATTI S,GUPTA AK. Imaging and interventions in hilar cholangiocarcinoma:A review[J]. World J Radiol,2015,7(2):28-44.

[3] GRUNNET M1,MAU-SORENSEN M. Serum tumor markers in bile duct cancer—a review[J]. Biomarkers,2014,19(6):437-443.

[4] SOARES KC,KAMEL I,COSGROVE DP,et al. Hilar cholangiocarcinoma:Diagnosis, treatment options, and management[J]. Hepatobiliary Surg Nutr,2014,3(1):18-34.

[5] DONG JH,FENG XB. Treatment of hilar cholangiocarcinoma in the era of precision surgery[J]. Chin J Dig Surg,2019,18(4):307-310.(in Chinese)董家鸿，冯晓彬．精准外科时代的肝门部胆管癌治疗[J]．中华消化外科杂志，2019,18(4):307-310.

[6] BISMUTH H,CORLETTE MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver[J]. Surg Gynecol Obstet,1975,140(2):170-178.

[7] BISMUTH H,NAKACHE R,DIAMOND T. Management strategies in resection for hilar cholangiocarcinoma[J]. Ann Surg,1992,215(1):31-38.

[8] WANG K,HE ZY,LIU YF,et al. The value of 256-MDCT three-dimensional image analysis in the treatment of hepatic hilar cholangiocarcinoma of Bismuth-Corlette III-type[J].Clin J Med Offic,2018,46(8):858-861.(in Chinese)王坤，何忠野，刘也夫，等．三维影像分析在Bismuth-Corlette III型肝门部胆管癌治疗中应用价值[J]．临床军医杂志，2018,46(8):858-861.

[9] TSAO JI,NIMURA Y,KAMIYA J,et al. Management of hilar cholangiocarcinoma:Comparison of an American and a Japanese experience[J]. Ann Surg,2000,232(2):166-174.

[10] CHENG QB,YI B,WANG JH,et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV[J]. Eur J Surg Oncol,2012,38(12):1197-1203.

[11] REA DJ,HEIMBACH JK,ROSEN CB,et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma[J]. Ann Surg,2005,242(3):451-458.

[12] DARWISH MURAD S,KIM WR,HARNOIS DM,et al. Efficacy of neoadjuvant chemoradiation,followed by liver transplantation,for perihilar cholangiocarcinoma at 12 US centers[J].Gastroenterology,2012,143(1):88-98.

[13] BURKE EC,JARNAGIN WR,HOCHWALD SN,et al. Hilar Cholangiocarcinoma:Patterns of spread,the importance of hepatic resection for curative operation,and a presurgical clinical staging system[J]. Ann Surg,1998,228(3):385-394.

[14] JARNAGIN WR,FONG Y,DEMATTEO RP,et al. Staging,resectability,and outcome in 225 patients with hilar cholangiocarcinoma[J]. Ann Surg,2001,234(4):507-517.

[15] HEMMING AW,REED AI,FUJITA S,et al. Surgical management of hilar cholangiocarcinoma[J]. Ann Surg,2005,241(5):693-699.

[16] ITO F,AGNI R,RETTAMMEL RJ,et al. Resection of hilar cholangiocarcinoma:Concomitant liver resection decreases hepatic recurrence[J]. Ann Surg,2008,248(2):273-279.

[17] AMIN MB,EDGE SB,GREENE FL,et al. AJCC Cancer Staging Manual[M]. 8th ed. New York:Springer,2017.

[18] EDGE SB,BYRD DR,COMPYON CC,et al. AJCC Cancer Staging Manual[M]. 7th ed. New York:Springer,2010.

[19] EBATA T,KOSUGE T,HIRANO S,et al. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas[J]. Br J Surg,2014,101(2):79-88.

[20] AOBA T,EBATA T,YOKOYAMA Y,et al. Assessment of nodal status for perihilar cholangiocarcinoma:Location,number,or ratio of involved nodes[J]. Ann Surg,2013,257(4):718-725.

[21] MAO K,LIU J,SUN J,et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma[J]. J Gastroenterol Hepatol,2016,31(2):417-426.

[22] SHIMIZU H,KIMURA F,YOSHIDOME H,et al. Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification[J]. J Hepatobiliary Pancreat Surg,2007,14(4):358-365.

[23] SASAKI R,MURATA S,ODA T,et al. Evaluation of UICCTNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma[J]. Langenbecks Arch Surg,2010,395(6):615-623.

[24] MIYAKAWA S,IAHIHARA S,HORIGUCHI A,et al. Biliary tract cancer treatment:5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan[J]. J Hepatobiliary Pancreat Surg,2009,16(1):1-7.

[25] GAZZANIGA GM,FAGGIONI A,FILAURO M. Surgical treatment of proximal bile duct tumors[J]. Int Surg,1985,70(1):45-48.

[26] GAZZANIGA GM,FILAURO M,BAGAROLO C,et al. Surgery for hilar cholangiocarcinoma:An Italian experience[J]. J Hepatobiliary Pancreat Surg,2000,7(2):122-127.

[27] DEOLIVEIRA ML,SCHULICK RD,NIMURA Y,et al. New staging system and a registry for perihilar cholangiocarcinoma[J]. Hepatology,2011,53(4):1363-1371.

[28] CHAITEERAKIJ R,HARMSEN WS,MARRERO CR,et al. A new clinically based staging system for perihilar cholangiocarcinoma[J]. Am J Gastroenterol,2014,109(12):1881-1890.

[29] SUN XZ. Prognosis influence for hilar cholangiocarcinoma and comparisons of prognosis values of Mayo staging and TMN staging systems[D]. Qingdao:Qingdao University,2017.(in Chinese)孙晓智．梅奥分期和TNM分期对肝门胆管癌预后的评估价值及其对比研究[D]．青岛:青岛大学，2017.

[30] BLECHACZ BR,SANCHEZ W,GORES GJ. A conceptual proposal for staging ductal cholangiocarcinoma[J]. Curr Opin Gastroenterol,2009,25(3):238-239.

[31] WU XL. The clinical value of Blechacz’s staging system in the preoperative assessment of hilar cholangiocarcinoma[D].Wuhan:Huazhong University of Science and Technology,2015.(in Chinese)吴晓龙．Blechacz分期在肝门部胆管癌术前评估中的应用价值[D]．武汉:华中科技大学，2015.

施引文献

资源附件(0)

访问统计